Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
Abstract Background Accumulating preclinical data indicate that targeting the SIRPα/CD47 axis alone or in combination with existing targeted therapies or immune checkpoint inhibitors enhances tumor rejection. Although several CD47-targeting agents are currently in phase I clinical trials and demonst...
Main Authors: | Erik Voets, Marc Paradé, David Lutje Hulsik, Sanne Spijkers, Wout Janssen, Joost Rens, Inge Reinieren-Beeren, Gilbert van den Tillaart, Sander van Duijnhoven, Lilian Driessen, Maurice Habraken, Peter van Zandvoort, Joost Kreijtz, Paul Vink, Andrea van Elsas, Hans van Eenennaam |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-12-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-019-0772-0 |
Similar Items
-
Cancer Therapy Targeting CD47/SIRPα
by: Nazli Dizman, et al.
Published: (2021-12-01) -
Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade
by: Abdullahi Alausa, et al.
Published: (2022-07-01) -
CD47–SIRPα-targeted therapeutics: status and prospects
by: R. Maute, et al.
Published: (2022-03-01) -
<i>Leishmania</i> Infection-Induced Proteolytic Processing of SIRPα in Macrophages
by: Hana Hirai, et al.
Published: (2023-04-01) -
Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils
by: Leonie M. Behrens, et al.
Published: (2022-07-01)